TMO Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
12.0B
+9.0%
11.0B
-9.9%
12.2B
+9.8%
11.1B
+2.5%
10.9B
Cost of Revenue
7.1B
+8.2%
6.6B
-8.7%
7.2B
+10.2%
6.5B
+1.4%
6.4B
Gross Profit
4.9B
+10.2%
4.4B
-11.6%
5.0B
+9.3%
4.6B
+3.9%
4.4B
Operating Expenses
2.8B
+8.9%
2.6B
-6.9%
2.8B
+4.2%
2.6B
+2.6%
2.6B
R&D
364.0M
+8.3%
336.0M
-5.6%
356.0M
+2.9%
346.0M
-1.7%
352.0M
SG&A
2.3B
+7.0%
2.2B
-7.3%
2.4B
+8.8%
2.2B
+1.0%
2.1B
Operating Income
2.1B
+12.0%
1.9B
-17.4%
2.3B
+16.3%
1.9B
+5.8%
1.8B
EBITDA
2.1B
-21.2%
2.6B
-12.6%
3.0B
-15.7%
3.6B
+106.3%
1.7B
Net Income
1.7B
+5.2%
1.7B
-15.9%
2.0B
+21.5%
1.6B
+0.2%
1.6B
EPS (Basic)
$4.68
+5.4%
$4.44
-15.4%
$5.25
+22.7%
$4.28
+0.0%
$4.28
EPS (Diluted)
$4.68
+5.6%
$4.43
-15.0%
$5.21
+22.0%
$4.27
-0.2%
$4.28
Shares (Diluted)
371.0M
-0.5%
373.0M
-1.1%
377.0M
-0.3%
378.0M
+0.0%
378.0M
Thermo Fisher Scientific (TMO) โ€” Financials